Compass Therapeutics, Inc. (CMPX)
| Market Cap | 334.96M +33.1% |
| Revenue (ttm) | n/a |
| Net Income | -68.17M |
| EPS | -0.40 |
| Shares Out | 180.09M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,874,411 |
| Open | 1.930 |
| Previous Close | 1.980 |
| Day's Range | 1.850 - 1.960 |
| 52-Week Range | 1.610 - 6.880 |
| Beta | 0.67 |
| Analysts | Strong Buy |
| Price Target | 10.58 (+468.82%) |
| Earnings Date | May 5, 2026 |
About CMPX
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, develops antibody-based therapeutics for the treatment of various human diseases in the United States. The company’s lead product candidate, tovecimig, is a bispecific antibody that targets delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A), which are critical to angiogenesis and tumor vascularization. It also develops CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells; C... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 15 analysts, the average rating for CMPX stock is "Strong Buy." The 12-month stock price target is $10.58, which is an increase of 468.82% from the latest price.
News
Compass Therapeutics to Participate in Upcoming May Investor Events
BOSTON, May 12, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to t...
Compass Therapeutics reports Q1 EPS (10c), consensus (10c)
“We recently announced positive data from our Phase 2/3 study of tovecimig and look forward to meeting with the FDA before filing a BLA later this year. Most patients with…
Compass Therapeutics Reports 2026 First Quarter Financial Results and Provides Corporate Update
BOSTON, May 05, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to t...
Compass Therapeutics price target lowered to $7 from $13 at Canaccord
Canaccord lowered the firm’s price target on Compass Therapeutics (CMPX) to $7 from $13 and keeps a Buy rating on the shares. The firm said Tovecimig+paclitaxel clearly improves progression-free survi...
Compass Therapeutics downgraded to Market Perform from Outperform at Raymond James
Raymond James analyst Sean McCutcheon downgraded Compass Therapeutics (CMPX) to Market Perform from Outperform with no price target after Compass disclosed survival outcomes from COMPANION-002, the Ph...
Compass Therapeutics price target lowered to $6 from $12 at Stifel
Stifel lowered the firm’s price target on Compass Therapeutics (CMPX) to $6 from $12 and keeps a Buy rating on the shares. The firm believes event-driven COMPANION-002 secondary endpoint data…
Compass Therapeutics selloff ‘an over-reaction,’ says Jefferies
Jefferies believes the 63% selloff in Compass Therapeutics (CMPX) is “an over-reaction” given the totality of the company’s data and the biliary tract cancer market opportunity. The key focus is…
Leerink says Compass data supports path forward for tovecimig in 2L BTC
Leerink notes that Compass Therapeutics (CMPX) announced progression free survival and overall survival results for tovecimig in second line biliary tract cancer from the randomized COMPANION-002 stud...
Compass Therapeutics, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
SAN DIEGO, April 27, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Compass Therapeutics, Inc. (NASDAQ: CMPX). The investigation focuses on C...
H.C. Wainwright keeps Buy rating on Compass Therapeutics after data
After Compass Therapeutics (CMPX) announced key secondary endpoints findings, including progression free survival and overall survival, from its COMPANION-002 randomized Phase 2/3 study in patients wi...
Compass Therapeutics Transcript: Study update
The COMPANION-002 trial in advanced biliary tract cancer met its primary and key secondary endpoints, with tovecimig plus paclitaxel significantly improving response rate and progression-free survival over paclitaxel alone. Crossover patients showed notable survival benefit, and safety was manageable.
Compass Therapeutics reports additional COMPANION-002 study results
Compass Therapeutics (CMPX) announced that it met the secondary endpoint of PFS and showed additional results in the randomized COMPANION-002 study, which evaluated tovecimig plus paclitaxel versus pa...
Tovecimig Demonstrates Statistically Significant Benefit in COMPANION-002 Randomized Phase 2/3 Study in Patients with Biliary Tract Cancer
Tovecimig (a DLL4 x VEGF-A bispecific antibody) in combination with paclitaxel demonstrated a highly statistically significant improvement versus paclitaxel alone in the key secondary endpoint of medi...
Compass Therapeutics to Announce Topline Secondary Endpoints from the Phase 2/3 COMPANION-002 Study of Tovecimig in Patients with Biliary Tract Cancer
BOSTON, April 24, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to...
Compass Therapeutics reports Q4 EPS (9c), consensus (9c)
“2025 marked a year of significant progress for Compass, highlighted by our lead asset tovecimig successfully meeting the primary endpoint of overall response rate in the COMPANION-002 Phase 2/3 study...
Compass Therapeutics Reports 2025 Financial Results and Provides Corporate Update
In the Phase 2/3 COMPANION-002 study of tovecimig (DLL4 x VEGF-A bispecific antibody) in patients with biliary tract cancer, the prespecified event threshold of 80% overall survival (OS) events was re...
Craig-Hallum bullish on Compass Therapeutics, initiates with a Buy
As previously reported, Craig-Hallum initiated coverage of Compass Therapeutics (CMPX) with a Buy rating and $15 price target The firm says Compass has a deep pipeline of next-gen bispecifics targetin...
Compass Therapeutics initiated with a Buy at Craig-Hallum
Craig-Hallum initiated coverage of Compass Therapeutics (CMPX) with a Buy rating and $15 price target
Compass Therapeutics price target raised to $13 from $10 at Canaccord
Canaccord raised the firm’s price target on Compass Therapeutics (CMPX) to $13 from $10 and keeps a Buy rating on the shares. The firm said they see upside to $13…
Compass Therapeutics Transcript: 44th Annual J.P. Morgan Healthcare Conference
Four clinical-stage antibody programs are advancing, with tovecimig showing strong efficacy in biliary tract cancer and poised for key survival readouts. Commercialization plans target a >$1B U.S. market, with expansion into other indications and strategic partnerships under consideration.
Compass Therapeutics provides corporate update
Compass Therapeutics (CMPX) provided a general business update highlighting progress throughout its pipeline of clinical-stage drug candidates. The analyses of progression-free survival and overall su...
Compass Therapeutics Provides Corporate Update
The analyses of progression-free survival (PFS) and overall survival (OS) remain on track for late Q1 2026 in the ongoing Phase 2/3 COMPANION-002 study of tovecimig (DLL4 x VEGF-A bispecific antibody)...
Compass Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to ...
Compass Therapeutics appoints Arjun Prasad as CCO, Cynthia Sirard as CMO
Compass Therapeutics (CMPX) announced the appointments of Arjun Prasad, MBA, MPH as Chief Commercial Officer and Cynthia Sirard, MD as Chief Medical Officer, both effective as of January 1, 2026.
Compass Therapeutics Announces Key Leadership Appointments
BOSTON, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to ...